Oct 8 (Reuters) - Rigel Pharmaceuticals Inc RIGL.O:
RIGEL ANNOUNCES FIRST PATIENT ENROLLED IN THE DOSE EXPANSION PHASE OF ITS PHASE 1B STUDY OF R289 IN PATIENTS WITH LOWER-RISK MDS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.